Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer. - Wikidata - wikimedia - TriplyDB

Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer.

Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer.

http://www.wikidata.org/entity/Q37277197

about

Potential Diagnostic, Prognostic and Therapeutic Targets of MicroRNAs in Human Gastric Cancer Small-molecule SMAC mimetics as new cancer therapeutics Discovering hidden connections among diseases, genes and drugs based on microarray expression profiles with negative-term filtering Analysis of inhibitor of apoptosis protein family expression during mammary gland development.Estrogen promotes breast cancer cell survival in an inhibitor of apoptosis (IAP)-dependent manner.EDL-360: A Potential Novel Antiglioma Agent.Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells.ck2-dependent phosphorylation of progesterone receptors (PR) on Ser81 regulates PR-B isoform-specific target gene expression in breast cancer cells.A novel antagonist to the inhibitors of apoptosis (IAPs) potentiates cell death in EGFR-overexpressing non-small-cell lung cancer cells Male breast cancer: an update in diagnosis, treatment and molecular profiling The Role of Interferon Regulatory Factor-1 (IRF1) in Overcoming Antiestrogen Resistance in the Treatment of Breast Cancer.LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signaling Cell death signaling and anticancer therapy Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers.Targeting inhibitors of apoptosis proteins (IAPs) for new breast cancer therapeutics Induction of apoptosis by fucoidan in human leukemia U937 cells through activation of p38 MAPK and modulation of Bcl-2 family Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization.A problem-solving education intervention in caregivers and patients during allogeneic hematopoietic stem cell transplantation.Role of Bcl-2 family proteins and caspases in the regulation of apoptosis.Combined modality therapy with TRAIL or agonistic death receptor antibodies.Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms.Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation.The interrelationship between HER2 and CASP3/8 with apoptosis in different cancer cell lines.MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition.Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.Smac mimetic compounds potentiate interleukin-1beta-mediated cell death Regulation of Apoptosis by HER2 in Breast Cancer.Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells.Inhibitor of Apoptosis Proteins: Promising Targets for Cancer Therapy.HER2+ breast cancer cells undergo apoptosis upon exposure to tannic acid released from remodeled cross-linked collagen type I.Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation.

P2860

Q26744362-923AFB4D-B8DF-4C03-929A-B4141CC6B4C5 Q26864204-9FE94A84-B323-475C-9409-2B48EE07FC96 Q28539530-ED68FF8A-F668-4BB9-B3D2-E92EAB562F9F Q33618500-CA588AA3-5BA1-49C1-A2C3-F0DBC645E7DF Q34378269-7515A8AE-DF73-4485-A894-E1ECF5CA684F Q34845272-C4AEC31D-D0EE-4D22-A130-89B49E9D48B3 Q34912378-6FE551C8-F1E0-43F7-BB37-84B64334CB8D Q35096710-C8A32AA6-6CB3-469D-882F-A69F03FFBF30 Q35338435-5459744C-D68B-4139-A11D-2B020D64AC8F Q35660943-196A838C-8725-4863-A98F-2ECF94FE45CF Q35684410-E12E3880-71C0-4E6F-99BA-FA72BC905712 Q35803259-3B3F124F-8E62-402F-8D9A-DE70815686BC Q35972102-BE0AD796-495F-43BE-A22F-ED4CFCEE2B8B Q36107033-0E331B3E-CD7A-43FC-A293-F4EFFCEAD25B Q36501732-26BEECD5-B1E8-4698-A4B8-632471981D57 Q37077640-F76A7EB8-4B78-426D-99E2-EA80F5278F0D Q37149249-B1D2AF51-ABB0-4BC9-BA0C-C21128042DF4 Q37473205-3CED5CAA-8B21-4D14-B65C-CCE02A2266C9 Q37826384-EA1389E4-EFEF-474A-9395-8E18773B4BC2 Q37832083-9382A0DE-D814-4306-BF1E-EFC113AAD938 Q38812867-A8CC7959-AD67-4C7B-B730-1BC63ADAD861 Q38823727-BE305CED-4D63-43A9-ABB7-2F11E6172B65 Q38833708-275D3E15-BAA0-4A35-8AB3-9459EA42B6A9 Q38959732-39077E8D-0E74-4F97-A577-006D7965A802 Q39411394-94ADD4E9-A216-4D2B-A327-5DD1E7534AEA Q39501392-30777B5E-ACD5-4185-8093-03487BB78213 Q39620638-F95DAC2F-DD09-4B3B-A43E-F00EFCC6D0B4 Q39642704-D6EB0E13-5A9B-4621-AA86-E38C1893A5AE Q39843650-7C07A642-005F-4BF8-B23F-C1FB9E605BAB Q41708988-A9CCFB2A-2E0D-4850-A308-161F238BB763 Q42949488-41EA7462-124A-40CF-B67E-D8221A4852EB Q47709744-E013C489-5EF3-42BE-9D7F-1F19D37C048C Q52653329-B8E3A917-A1BA-434D-B1AB-C46E65599B3B

P2860

Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer.

http://www.wikidata.org/entity/Q37277197

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 29 June 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeting inhibitor of apoptos ...... antagonists in breast cancer.

@en

Targeting inhibitor of apoptos ...... antagonists in breast cancer.

@nl

type

label

Targeting inhibitor of apoptos ...... antagonists in breast cancer.

@en

Targeting inhibitor of apoptos ...... antagonists in breast cancer.

@nl

prefLabel

Targeting inhibitor of apoptos ...... antagonists in breast cancer.

@en

Targeting inhibitor of apoptos ...... antagonists in breast cancer.

@nl

P1433

Q37277197-12D87A3C-2A6F-4189-9F31-F7AF2B943660

P1476

Q37277197-A21794BA-FF3F-4350-81D9-2B55FD133241

P2093

Q37277197-598D4A35-A97C-46DD-B389-776911699F0A

Q37277197-6E16D5D7-8883-4837-A3CB-DB54ACAD5939

Q37277197-8929FD0D-19F3-4D7D-A1F1-32ED4791859F

Q37277197-BD6C5E57-DF20-4748-80FA-729B00063167

Q37277197-CA9D6F04-316F-427F-8701-86C7E2AD4DEC

Q37277197-E5ACED42-6C2D-456D-A2E4-217525A7AC3C

Q37277197-FD40231E-5438-42BD-AF1D-6F2F821711BA

P2860

Q37277197-0A175EC7-CC31-4FEF-8289-7518890B6F0B

Q37277197-0C8B4C02-764E-4CEF-8079-B1BC33828807

Q37277197-1D192A11-1778-47EE-B111-AFF590BAE964

Q37277197-1EB671AF-C212-42BB-A759-4030206D99DC

Q37277197-1F65C8B2-727C-41CC-803A-09A99F5119C0

Q37277197-206BA86D-84CE-4F47-A9F1-65C2D37C56A1

Q37277197-25A2E92E-B438-4792-8507-956982F88B70

Q37277197-26593552-A8EB-402B-9E83-1249E543A0D1

Q37277197-2DF4719A-6126-4796-982B-65269093C10C

Q37277197-3544953E-65C0-43FB-A5AD-7037B6FE773A

P2888

Q37277197-04C17FA0-A099-47ED-B610-93A5D9FD182A

P304

Q37277197-05E1E82B-545F-4E9F-AE23-FD2E6263A82B

P31

Q37277197-2A97A0FA-E741-4C55-B06B-43123FB2DB14

P356

Q37277197-B1BECE02-7711-4879-B375-99944069DA89

P433

Q37277197-DAC878B5-2FE0-45EB-8772-213E5CBEBF77

P478

Q37277197-EED13AA8-A4D8-499E-96FA-1799A3110E65

P577

Q37277197-5D9830C0-A378-4DA7-A0B6-8D6992824287

P5875

Q37277197-7EA30285-989D-41D4-8A84-8CE6C27AF76A

P6179

Q37277197-34E0E6BA-ED05-4A1D-82D8-BB722AFF1E7C

P698

Q37277197-1AE76A66-3BB6-40F6-AE66-A829BE1E8175

P921

Q37277197-614ED6F5-3039-48B5-BC02-3A41D80C13D3

P932

Q37277197-98A34582-8828-462A-A57C-ACD126DC2E6B

P356

P1433

Breast Cancer Research

P1476

Targeting inhibitor of apoptos ...... antagonists in breast cancer.

@en

P2093

Charles H Streuli

http://www.w3.org/2001/XMLSchema#string

Fiona M Foster

http://www.w3.org/2001/XMLSchema#string

Jolanta Tanianis-Hughes

http://www.w3.org/2001/XMLSchema#string

Keith Brennan

http://www.w3.org/2001/XMLSchema#string

Nigel J Bundred

http://www.w3.org/2001/XMLSchema#string

Robert B Clarke

http://www.w3.org/2001/XMLSchema#string

Thomas W Owens

http://www.w3.org/2001/XMLSchema#string

P2860

IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis

TNF-alpha induces two distinct caspase-8 activation pathways

Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death

Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach

Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.

Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition

The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7

Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines.

Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias.

P2888

P304

R41

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR2328

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26327706

http://www.w3.org/2001/XMLSchema#string

P6179

1026195826

http://www.w3.org/2001/XMLSchema#string

P698

19563669

http://www.w3.org/2001/XMLSchema#string

P921

apoptotic process

P932

2716510

http://www.w3.org/2001/XMLSchema#string